Medtronic Earnings Call Transcripts
Fiscal Year 2026
-
Accelerated product launches, strategic M&A, and portfolio actions have driven strong momentum, with high single-digit EPS growth targeted for next year. CAS, renal denervation, and Altaviva are key growth drivers, while the MiniMed separation and selective commercialization of Hugo and Stealth Access platforms support long-term value creation.
-
Middle East exposure and oil price impacts are minimal, with logistics well managed and cost effects delayed by inventory cycles. The MiniMed separation is on track, supporting focused growth and higher margins, while CAS, Hugo, and Ardian franchises are set to drive accelerating growth and EPS leverage into 2027.
-
Q3 FY26 delivered 6% organic revenue growth and strong performance across cardiovascular, diabetes, and innovation-driven segments. Guidance for FY26 and FY27 remains robust, with high single-digit EPS growth expected, supported by new product launches and disciplined capital allocation.
-
Medtronic is accelerating growth through four major product launches, increased R&D investment, and a focused portfolio strategy. Operational improvements and new board committees are driving margin expansion and faster decision-making, while tuck-in M&A and a diabetes spin-off support future innovation.
-
Q2 delivered strong revenue and EPS growth, driven by robust performance in PFA, Simplicity, and AltaViva launches. Fiscal 2026 guidance was raised for both revenue and EPS, with accelerating momentum expected from key growth drivers and continued investment in innovation.
-
Q1 FY26 saw 4.8% organic revenue growth and EPS above guidance, led by strong Cardiovascular and Diabetes performance. Full-year EPS guidance was raised, with accelerating growth expected from new product launches and business mix improvements. Governance enhancements and the Diabetes separation are set to drive further value creation.
Fiscal Year 2025
-
AltaViva, a newly FDA-approved implantable tibial neuromodulation device, targets a large, underserved UUI market with a minimally invasive, long-lasting solution. Early clinical data show strong efficacy in refractory patients, and aggressive launch strategies are driving rapid adoption and awareness.
-
Growth is set to accelerate, with a focus on innovation, margin recovery, and high single-digit EPS growth. Operational improvements, targeted M&A, and enhanced board oversight support this strategy, while key pipeline products like CAS, Hugo, and RDN drive future value.
-
A unified supply chain and lean manufacturing have driven significant cost savings, with materials, labor, and logistics all contributing to improved margins. AI and automation are enhancing efficiency, while risk management and network optimization support resilience. Ongoing initiatives are expected to sustain 5% gross savings annually.
-
Leadership emphasized operational discipline, data-driven capital allocation, and aggressive investment in high-growth platforms like CAS, RDN, and Hugo™. The Diabetes business separation is on track, with a focus on portfolio synergies and margin expansion. Board and operational changes support sustained growth and innovation.
-
Management is focused on capitalizing on innovation, accelerating growth, and improving margins through operational discipline, targeted M&A, and increased R&D. Key growth drivers include new product launches in cardiac ablation, diabetes, and renal denervation, with a strong financial outlook for 2027.
-
The event highlighted a strategic focus on innovation-driven growth, portfolio optimization, and operational improvements, including the planned diabetes business separation. Key growth drivers include AI, robotics, and sensing technologies, with strong financial guidance and robust segment outlooks in cardiac ablation, renal denervation, and surgical robotics.
-
Q4 revenue grew 5.4% organically, with strong performance in cardiovascular, neuromodulation, and diabetes. The company announced a planned separation of its diabetes business, expects ~5% organic revenue growth and ~4% EPS growth in FY26, and projects high single-digit EPS growth in FY27 post-separation.
-
Q3 delivered 4.1% organic revenue growth and 6.9% EPS growth, led by strong performances in Cardiac Ablation, Neuromodulation, and Diabetes. Margin expansion, innovation, and robust international growth offset Medical Surgical headwinds, with guidance reaffirmed for FY25.
-
Momentum is accelerating across high-growth medtech segments, with major product launches in cardiac ablation, hypertension, neuromodulation, and diabetes. Operational efficiencies, disciplined capital allocation, and a robust innovation pipeline are expected to drive margin improvement and sustained earnings growth.
-
Reported 5% organic revenue growth and 8% EPS growth (constant currency), raising full-year guidance for both revenue and EPS. Strong performance in diabetes, neuroscience, and cardiovascular segments, with innovation and new product launches driving diversified growth.
-
Q1 delivered 5.3% organic revenue growth and 3% adjusted EPS growth, exceeding guidance. Strong performance in diabetes, cardiac ablation, and neuromodulation drove results, with FY25 guidance raised for both revenue and EPS. FX headwinds expected to ease in the second half.
Fiscal Year 2024
-
Strong innovation and digital integration are driving healthy growth in medtech, with new technologies like PFA and AI-based products supporting both top and bottom line improvements. China localization, disciplined capital allocation, and robust performance in spine, neuromodulation, and cardiac rhythm are key focus areas.
-
Innovation in high-growth areas and operational improvements are driving stable mid-single-digit revenue growth, with robotics, PFA, and next-gen products set to expand markets. Financial discipline and targeted capital allocation support a return to high single-digit EPS growth.